Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
2.4
-155.64%
20%
—
-9.91%
60%
—
5 Years
Score2.4
Net Growth-155.64%
Net Trend20%
Net Income Consistency—
Rev Growth-9.91%
Rev Trend60%
Revenue Consistency—
Tscan Therapeutics Inc fundamental performance
Between 2021 and 2025, revenue grew from $ 10M to $ 10M and net income went from -$ 48M to -$ 129M. Revenue increased in 60% of the years measured; net income in 20%.
Tscan Therapeutics Inc currently holds a 5-year HDB Score of 2.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 0.77 | — |
1 Year2025-08-12 | $ 1.67 | -53.71% |
5 Years2021-08-12 | $ 10.09 | -92.34% |
All Time2021-07-16 | $ 10.50 | -92.64% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-07-16 |
|---|---|---|---|---|
| Price | $ 0.77 | $ 1.67 | $ 10.09 | $ 10.50 |
| Return | — | -53.71% | -92.34% | -92.64% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 9M | -$ 124M | $ 128M |
| 2025 | $ 10M | -$ 129M | $ 152M |
| 2024 | $ 2M | -$ 127M | $ 290M |
| 2023 | $ 21M | -$ 89M | $ 192M |
| 2022 | $ 13M | -$ 66M | $ 120M |
| IPO2021 | $ 10M | -$ 48M | $ 161M |
Explore beyond TCRX
You're looking at Tscan Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
